Alterations in expression of the multidrug resistance-associated protein (MRP) gene in high-grade transitional cell carcinoma of the bladder

British Journal of Cancer

Volumn 73, Issue 5, 1996, Pages 659-666

  Clifford, S C ^a   Neal, D E ^a   Lunec, J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Bladder cancer; Chemotherapy; Multidrug resistance associated protein (MRP); Polymerase chain reaction (PCR)

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIRUBICIN; MESSENGER RNA; METHOTREXATE; VINBLASTINE;

ARTICLE; BLADDER; BLADDER BIOPSY; BLADDER CANCER; CANCER GENETICS; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MONONUCLEAR CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TESTIS; TRANSITIONAL CELL CARCINOMA; TUMOR GROWTH;

EID: 0030029210     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.115     Document Type: Article

References (30)

1. ALMQUIST KC, LOE DW, HIPFNER DR, MACKIE JE, COLE SPC AND DEELEY RG (1995). Characterisation of the Mr 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumour cells. Cancer Res., 55, 102-110.
2. BARRAND MA, HEPPELL-PARTON AC, WRIGHT KA, RABBITTS PH AND TWENTYMAN PR. (1994). A 190-kilodalton protein over-expressed in non-p-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene. J. Natl Cancer Inst., 86, 110-117.
3. BORDOW SB, HABER M, MADAFIGLIO J, CHEUNG B, MARSHALL GM AND NORRIS MD. (1994). Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the n-myc oncogene in childhood neuroblastoma. Cancer Res., 54, 5036-5040.
4. BURGER H, NOOTER K, SONNEVELD P, VAN WINGERDEN KE, ZAMAN GJR AND STOTER G. (1994). High expression of the multidrug resistance-associated protein (MRP) in chronic and prolymphocytic leukaemia. Br. J. Haematol., 88, 348-356.
5. CLIFFORD SC. (1994). Determinants of chemosensitivity in primary human bladder cancer. PhD Thesis, University of Newcastle upon Tyne.
6. CLIFFORD SC, THOMAS DJ, NEAL DE AND LUNEC J. (1994). Increased MRD1 gene transcript levels in high-grade carcinoma of the bladder determined by quantitative PCR-based assay. Br. J. Cancer, 69, 680-686.
7. COLE SPC, BHARDWAJ G, GERLACH JH, MACKIE JE, GRANT, CE, ALMQUIST KE, STEWART AJ, KURZ EU, DUNCAN AMV AND DEELEY RG. (1992). Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 258, 1650-1654.
8. COLE SPC, SPARKS KE, FRASER K, LOE DW, GRANT CE, WILSON GM AND DEELEY RG. (1994). Pharmacological characterisation of multidrug resistant MRP-transfected human tumour cells. Cancer Res., 54, 5902-5910.
9. DAVIES JM. (1992). Occupational and environmental factors in bladder cancer. In Scientific Foundations of Urology, 2nd edn, Chisholm GD and Innes-William D (eds), pp. 723-727. Heinemann: London.
10. ENDICOTT JA AND LING V. (1989). The biochemistry of P-glycoprotein mediated resistance. Annu. Rev. Biochem., 58, 136-171.
11. FLENS MJ, IZQUIERDO MA, SCHEFFER GL, FRITZ JM, MEIJER CJLM, SCHEPER RJ AND ZAMAN GJR. (1994). Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumour cells by monoclonal antibodies. Cancer Res., 54, 4557-4563.
12. GONZALEZ IL AND SCHMICKEL RD. (1986). The human 18S ribosomal RNA gene: evolution and stability. Am. J. Hum. Genet., 38, 419-427.
13. GRANT CE, VALDIMARSSON G, HIPFNER DR, ALMQUIST KC, COLE SPC AND DEELEY RG. (1994). Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res., 54, 357-361.
14. HARKER WG, MEYERS FJ, FREIHA, FS, PALMER JM, SHORTLIFFE LD, HANNIGAN JF, MCWHIRTER KM AND TORTI FM. (1985). Cisplatin, methotrexate and vinblastine (CMV): an effective chemotherapy reigmen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J. Clin. Oncol., 3, 1463-1470.
15. HASEGAWA S, ABE T, NAITO S, KOTOH S, KUMAZAWA J, HIPFNER DR, DEELEY DR, COLE SPC AND KUWANO M. (1995). Expression of multidrug-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Br. J. Cancer, 71, 907-913.
16. HIPFNER DR, GAULDIE SD, DEELEY RG AND COLE SPC. (1994). Detection of the Mr 190,000 multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res., 54, 5788-5792.
17. LIPPONEN PK, ESKELINEN HJ, JAUHIAINEN K, HARJU E AND TERHO R. (1993). Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer. Eur. J. Cancer, 29A, 1757-1761.
18. LOWE T, SHREFKIN J, YANG SQ AND DIFFENBACH CW. (1990). A computer program for selection of oligonucleotide primers for polymerase chain reactions. Nucl. Acid Res., 18, 1757-1761.
19. MARSH W, SICHERI D AND CENTER MS. (1986). Isolation and characterisation of adriamycin resistant HL60 cells which are not defective in the initial intracellular accumulation of drug. Cancer Res., 46, 4053-4057.
20. MOSTOFI FK, DAVIS CJ AND SESTERHENNIA. (1988). Pathology of tumours of the urinary tract. In Diagnosis and Management of Genitourinary Cancer. Skinner DG and Lieskovsky G (eds) pp. 83-117. WB Saunders: London.
21. MULLER M, MEIJER C, ZAMAN GJR, BORST P, SCEPER RJ, MULDER NH, DE VRIES EGE AND JANSEN PLM. (1994). Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione s-conjugate transport. Proc. Natl Acad. Sci. USA, 91, 13033-13037.
22. NOONAN KE, BECK C, HOLZMAYER TA, CHIN JE, WUNDER JS, ANDRULIS IL, GAZDAR AF, WILLMAN CL, GRIFFITH B, VON HOFF DD AND RONINSON IB. (1990). Quantitative analysis of MDR1 gene expression in human tumors by polymerase chain reaction. Proc. Natl Acad. Sci. USA, 87, 7160-7164.
23. RAGHAVAN D. (1988). The management of bladder cancer: current practice and future prospects. In Management of Bladder Cancer. Raghaven D (ed.) pp. 317-332. EJ Arnold: London.
24. SCHNEIDER E, COWAN KH, BADER H, TOOMEY S, SCHWARTZ GN, KARP JE, BURKE PJ AND KAUFMANN SH. (1995). Increased expression of the mutlidrug resistance-associated gene in relapsed acute leukaemia. Blood, 85, 186-193.
25. SLOVAK ML, PELKEY HO J, BHARDWAJ G, KURZ EU, DEELEY RG AND COLE SPC. (1993). Localisation of a novel multidrug resistance associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res., 53, 3221-3225.
26. STERNBERG CN, YAGODA A, SCHER HI, WATSON RC, HERR HW, MORSE MJ, SOGANI PC, VAUGHAN KD, BANDER N, WEISELBERG LR, GELLER N, HOLLANDER PS, LIPPERMAN R, FAIR WR AND WHITMORE WF. (1988). MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) for advanced transitional cell carcinoma of the urothelium. J. Urol. 137, 663-666.
27. UICC. (1978). TNM Classification of Malignant Tumors, Third edition. International Union against Cancer: Geneva.
28. ZAMAN GJR, VERSTANTVOORT CHM, SMIT JJM, EIJDEMS EWHM, DE HAAS M, SMITH AJ, BROXTERMAN HJ, MULDER NH, DE VRIES EGE, BAAS F AND BORST P. (1993). Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res., 53, 1747-1750.
29. ZHU Q AND CENTER MS. (1994). Cloning and sequence analysis of the promoter region of the MRP gene of HL60 cells isolated for resistance to doxorubicin. Cancer Res., 54, 4488-4492.
30. ZIJLSTRA JG, DE VRIES EGE AND MULDER NH. (1987). Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res. 47, 1780-1784.